Page 221 - 2021_04-Haematologica-web

BV-DHAP in relapsed or refractory Hodgkin lymphoma
Oncol. 2018;29(3):724-730.
21. Younes A, Gopal AK, Smith SE, et al. Results
of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refrac- tory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
22. Hagenbeek A, Mooij H, Zijlstra J, et al. Phase 1 dose-escalation study of brentuximab- vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as sal- vage treatment in relapsed/refractory classi- cal Hodgkin lymphoma: the Transplant BRaVE study. Haematologica. 2018; 104(4):e151-e153.
23. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.
24. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
25. Natkunam Y, Gratzinger D, Chadburn A, et al. Immunodeficiency-associated lympho- proliferative disorders: time for reappraisal? Blood. 2018;132(18):1871-1878.
26. Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010;28(34):5074-5080.
27. Moskowitz AJ, Schoder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017; 130(20):2196-2203.
28.Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term out-
come after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625-633.
29. Hahn T, McCarthy PL, Carreras J, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013; 19(12):1740-1744.
30.Santoro A, Mazza R, Pulsoni A, et al. Bendamustine in combination with gemc- itabine and vinorelbine is an effective regi- men as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol. 2016;34(27):3293-3299.
course, and outcome. Biol Blood Marrow
Transplant. 2010;16(2):157-168.
36. Moskowitz CH, Nademanee A, Masszi T, et
al. Brentuximab vedotin as consolidation therapy after autologous stem-cell trans- plantation in patients with Hodgkin's lym- phoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-1862.
37. Sarkozy C, Copie-Bergman C, Damotte D, et al. Gray-zone lymphoma between cHL and large B-cell lymphoma. A histopatho- logic series from the LYSA. Am J Surg Pathol. 2019;43(3):341-351.
38. Pilichowska M, Pittaluga S, Ferry JA, et al. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Advances. 2017;1(26):2600-2609.
39. Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lym- phomas, Hodgkin lymphomas, and histio- cytic/dendritic cell neoplasms. Expert Rev Hematol. 2017;10(3):239-249.
40. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical out- comes. J Clin Oncol. 2008;26(25):4124-4130.
41.Mettler J, Muller H, Voltin CA, et al. Metabolic tumour volume for response pre- diction in advance-stage Hodgkin lym- phoma. J Nucl Med. 2019;60(2):207-211.
42. El-Galaly TC, Villa D, Gormsen LC, Baech J, Lo A, Cheah CY. FDG-PET/CT in the man- agement of lymphomas: current status and future directions. J Intern Med. 2018; 284(4):358-376.
31.
Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531-2533.
32.Sorigue M, Sancho JM, Pineda A, et al. Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. Leuk Res. 2017;58:98-101.
33. McKeage M. Comparative adverse effect profiles of platinum drugs. Drug Safety. 1995;13(4):228-244.
34. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman T. Interim results of brentuximab vedotin in combina- tion with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183-1194.
35. Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical
haematologica | 2021; 106(4)
1137